Kansas City Business Journal: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'

A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine. The study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity. 

The results of the STEP-HFpEF study are likely to be a paradigm shift in treating these patients. The study was the leading presentation at the European Society of Cardiology (ESC) 2023 Congress, the largest cardiovascular conference in the world.

Read the Kansas City Business Journal's full article: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Dec. 20, 2023

Kansas City Business Journal: Kansas City-Led Clinical Trial on Popular Weight-Loss Drug is Honored as a 'Breakthrough of the Year'
A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.
Aug. 28, 2023

New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.